$4.32
-0.27 (-5.88%)
Open$4.59
Previous Close$4.59
Day High$4.69
Day Low$4.30
52W High$19.15
52W Low$3.92
Volume—
Avg Volume130.3K
Market Cap38.11M
P/E Ratio1.17
EPS$3.13
SectorBiotechnology
Analyst Ratings
Buy
11 analysts
Price Target
+63.0% upside
Current
$4.32
$4.32
Target
$7.04
$7.04
$5.84
$7.04 avg
$9.41
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 72.96M | 58.91M | 4.60M |
| Net Income | 19.75M | 14.35M | -132,709 |
| Profit Margin | 27.1% | 25.7% | -2.9% |
| EBITDA | 22.92M | 17.58M | -214,542 |
| Free Cash Flow | — | — | -85,981 |
| Rev Growth | +23.9% | +23.9% | -8.7% |
| Debt/Equity | 0.04 | 0.04 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |